Argatroban anticoagulation in patients with heparin-induced thrombocytopenia

Archives of Internal Medicine

Volumn 163, Issue 15, 2003, Pages 1849-1856

  Lewis, Bruce E ^a,e   Wallis, Diane E ^b,f   Leya, Fred ^a   Hursting, Marcie J ^c   Kelton, John G ^d  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b Midwest Heart Specialists   (United States)

^c Clinical Science Consulting   (United States)

^d MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^e TEXAS BIOTECHNOLOGY CORPORATION   (United States)

^f GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN; HEPARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS;

AGED; ANTICOAGULANTS; ANTITHROMBINS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMORRHAGE; HEPARIN; HUMANS; MALE; MIDDLE AGED; PIPECOLIC ACIDS; PROSPECTIVE STUDIES; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0038285887     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.163.15.1849     Document Type: Article

References (28)

1. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101:502-507.
2. Walls JT, Curtis JJ, Silver D, Boley TM, Schmaltz RA, Nawarawong W. Heparin-induced thrombocytopenia in open heart surgical patients: sequelae of late recognition. Ann Thorac Surg. 1992;53:787-791.
3. Wallis DE, Workman DL, Lewis BE, Steen L, Pifarre R, Moran JF. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med. 1999;106:629-635.
4. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330-1335.
5. Warkentin TE, Hayward CPM, Boshkov LK, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood. 1994;84:3691-3699
6. Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest. 1994;93:81-88.
7. Cines DB, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. N Engl J Med. 1987;316:581-589.
8. Warkentin TE. Heparin-induced thrombocytopenia: a clinicopathologic syndrome. Thromb Haemost. 1999;82:439-447.
9. Greinacher A, Warkentin TE. Treatment of heparin-induced thrombocytopenia: an overview. In: Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia. 2nd ed. New York, NY: Marcel Dekker Inc; 2001:291-322.
10. Greinacher A, Amiral J, Dummel V, Vissac A, Kieffel V, Mueller-Eckhardt C. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay. Transfusion. 1994;34:381-385.
11. Warkentin TE, Elavathil LJ, Hayward CPM, Johnston MA, Russett JI, Kelton JG. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann intern Med. 1997;127:804-812.
12. Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemost. 1993;70:554-561.
13. Berry CN, Girardot C, Lecoffre C, Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant hirudin. Thromb Haemost. 1994;72:381-386.
14. Walenga JM, Koza MJ, Lewis BE, Pifarré R. Relative heparin-induced thrombocytopenic potential of low molecular weight heparins and new antithrombotic agents. Clin Appl Thromb Hemost 1996;2(suppl 1):S21-S27.
15. Greinacher A, Völpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation. 1999;99:73-80.
16. Greinacher A, Janssens U, Berg G, et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation. 1999;100:587-593.
17. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001;103:1838-1843.
18. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy. 2000;20:318-329.
19. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;344:1286-1292.
20. Warkentin TE, Sheppard JI, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood. 2000;96:1703-1708.
21. King DJ, Kelton JG. Heparin-associated thrombocytopenia. Ann Intern Med. 1984; 100:535-540.
22. Vanholder R, Camez A, Veys N, Van Loo A, Dhondt AM, Ringoir S. Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients. Thromb Haemost. 1997;77:650-655.
23. Eichler P, Friesen H-J, Lubenow N, Jaeger B, Greinacher A. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood. 2000;96:2373-2378.
24. Walenga JM, Ahmad S, Hoppensteadt D, Iqbal O, Hursting MJ, Lewis BE. Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia. Thromb Res. 2002;105: 401-405.
25. Refludan (lepirudin [rDNA] for injection) [package insert]. Kansas City, Mo: Hoechst Marion Roussel; 1998.
26. Sheth SB, DiCicco RA, Hursting MJ, Montague T, Jorkasky DK. Interpreting the international normalized ratio (INR) in individuals receiving argatroban and warfarin. Thromb Haemost. 2001;85:435-440.
27. Hiatt BK, Macfarlane DE, Hursting MJ. Transition from argatroban to warfarin in patients with heparin-induced thrombocytopenia [abstract]. Blood. 2001;98(pt 2):91b.
28. Kelton JG, Hursting MJ, Lewis BE. The predictors of clinical outcome in patients with heparin-induced thrombocytopenia [abstract]. Blood. 2001;98(pt 1):36a.